The oncogenetic role of stanniocalcin 1 in lung adenocarcinoma: a promising serum candidate biomarker for tracking lung adenocarcinoma progression

• DOI: 10.1007/s13277-015-4431-x
• Publication Date: 2015-11-17T21:11:39Z
• Authors: Yu-Zhen Du; Xiao-Hua Gu; Shao-Fei Cheng; Li Li; Hua Liu; Liu-Ping Hu; Feng Gao
• Keywords: Tumor progression

Stanniocalcin 1 (STC1) is reported to functionally participate in the development of several cancers. However, role STC1 tumorigenesis and progression lung adenocarcinoma remains be fully elucidated. Here, we found that average levels serum were 5.47, 5.53, 6.94 ng/mL (P = 0.0045) healthy subjects patients with at tumor stages I-II III-IV according Union for International Cancer Control (UICC), respectively. Subsequently, positive correlation between expression level tissues was confirmed by immunohistochemical staining assay. Additionally, studies STC1-overexpressing or STC1-silenced stable cell lines showed increased proliferation promoting G1/S transition cycle via up-regulating cyclin B1 E. Moreover, also inhibited apoptosis anti-apoptosis proteins Bcl-2 Bcl-xl down-regulating pro-apoptosis Bax, Bak, Bid activation ERK JNK signaling pathway. In addition, neutralization monoclonal antibody significantly A549 cells. Taken together, our findings strongly suggest elevated protein stage promotes positively associates cancer progression, which may potential value as marker clinical tracking progression.